Clinical Trial Update: Crizotinib Continuation Clinical Study [Phase 4]

View source ↗

Summary

A Phase 4 continuation study of crizotinib sponsored by Pfizer is currently active but not recruiting. The study investigates crizotinib in non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Inflammatory Myofibroblastic Tumor
• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: NSCLC, ALCL | Phase 4 | Status: ACTIVE_NOT_RECRUITING